Belite Bio Announces Registered Direct Offering of $15 Million
The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio,...
Staff
Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage...
Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company with a sole focus of closing...
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates
-- Announced positive data from two patients in Phase 1/2 clinical trial in Chronic Granulomatous Disease (CGD), providing clinical proof-of-concept...
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the...
Bionano Announces Publication Showing Utility of Optical Genome Mapping in Clinical Research of Infant & Toddler T-ALL
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a peer-reviewed publication from a...
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
Topline results from CATT1 Phase 3 trial expected in second half of 2026HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE)...
Izotropic Launches Podcast Episode #1: Beyond the Mammogram: Rethinking the Future of Breast Imaging
VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- via IBN –Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF)...
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a...
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025
DURHAM, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable,...
Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments
The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025
Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ETPORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell...
Nualtis Announces Strategic Partnership with OrthoNu for Innovative Orthodontic Care Products
MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Nualtis (formerly IntelGenx Corp.), a leader in oral film drug delivery technologies, today...
UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results
ZUSDURI™ (mitomycin) for intravesical solution now available as the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk...
Milestone Achievement for Hospital Using Catheter Precision’s VIVO System
Heart Hospital of New Mexico is the First Hospital to Complete 200 Ventricular Ablation Procedures with the VIVO System EP...
Annovis Completes Full Patent Transfer to Crystal Buntanetap
Annovis achieves comprehensive intellectual property (IP) protection now covering both the original semi-crystalline and new crystalline forms of buntanetap. Both...
Route 92 Medical Files Patent Infringement Suit Against Balt
SAN MATEO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated...
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Topline results for the Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism on track for Q3 2025 Imapextide (MBX 1416)...
TRACEABILITY, QUALITY, SAFETY: OVER A DECADE OF ANTARES VISION GROUP’S CONTRIBUTION TO THE AFRICAN PHARMACEUTICAL SECTOR
The Group's advanced technologies and made in Italy quality ensure compliance to global standards, supply chain integrity and patient safety...
1.2 Million Healthcare Devices and Systems Found Exposed Online – Patient Records at Risk of Exposure, Latest Research from Modat
THE HAGUE, Netherlands, Aug. 7, 2025 /PRNewswire/ -- Over 1.2 million internet-connected healthcare devices and systems with exposure that endanger patient...